Skip to content

Daratumumab

Daratumumab is a monoclonal antibody targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. It works by inducing cell death through immune-mediated mechanisms and direct apoptosis, making it a valuable treatment in oncology. Its relevance to longevity and health optimization lies in its potential to modulate the immune system and target cancerous cells, although its primary use is currently in cancer therapy.

Intelligence Profile

Clinical Applications

Daratumumab is primarily used in the treatment of multiple myeloma, a type of blood cancer. Clinical studies and trials have provided insights into its efficacy and application:

  1. Multiple Myeloma:

    • Daratumumab has shown effectiveness in treating newly diagnosed and relapsed or refractory multiple myeloma. It is often part of combination therapies, enhancing treatment outcomes.
    • A real-world retrospective analysis highlighted its application in relapsed or refractory cases, supporting its use in various clinical settings (Asia-Pacific Journal of Clinical Oncology, 2026).
    • Clinical trials such as NCT03311828 and NCT03224507 have investigated its potential to achieve deep remission and evaluated its role alongside other treatments, like Elranatamab (NCT05020236).
  2. Smoldering Multiple Myeloma and MGUS:

    • Daratumumab is being studied for its role in high-risk smoldering multiple myeloma, aiming for early intervention to prevent disease progression (NCT03236428).
  3. Kidney Transplant Rejection:

    • An article in the Clinical Kidney Journal (2026) provided evidence that daratumumab may help manage antibody-mediated kidney allograft rejection, offering a potential therapeutic approach beyond oncology.
  4. Light-Chain Amyloidosis:

    • Though a study (NCT05486481) was withdrawn, daratumumab is being explored in systemic light-chain amyloidosis, particularly when translocation (11;14) is present, indicating ongoing interest in expanding its clinical applications.
  5. Safety Concerns:

    • Studies have noted a high prevalence of iron deficiency in patients receiving daratumumab, necessitating monitoring during treatment (British Journal of Haematology, 2026).
    • Managing infusion-related reactions is crucial, with research into premedication approaches to minimize these effects (Biological & Pharmaceutical Bulletin, 2026).

Overall, daratumumab's roles across multiple conditions and ongoing studies suggest its expanding use beyond its established indications in multiple myeloma. The evidence supports its integration into treatment protocols, reflecting meaningful advancements in managing complex conditions.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.